I-O Optimise: a multinational real-world research initiative in thoracic malignancies

S Ekman, F Griesinger, P Baas, D Chao, C Chouaid, JC O'Donnell, JR Penrod, M Daumont, L Lacoin, A McKenney, M Khovratovich, REJ Munro, I Durand-Zaleski, SP Johnsen

Future Oncol 2019;15:1551-1163

I-O Optimise® is an ongoing collaborative real-world research initiative focused on building a multinational data platform that leverages existing real-world data sources to provide ongoing, timely, and novel insights into real-world treatment patterns and outcomes in patients with lung cancer

View: Full publication summary

Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative

M Soares, L Antunes, P Redondo, M Borges, R Hermans, D Patel, F Grimson, R Munro, C Chaib, L Lacoin, M Daumont, JR Penrod, JC O'Donnell, MJ Bento, FR Goncalves

BMC Pulm Med. 2020;20:240. DOI: 10.1186/s12890-020-01270-z

This retrospective cohort study of 1,008 patients with incident advanced non-small cell lung cancer (NSCLC), as part of the I-O Optimise research initiative, evaluated real-world treatment patterns and survival prior to immunotherapy reimbursement at IPO-Porto hospital in Portugal (2012–2017).

View: Full publication summary